Table Graph
      published meta-analysis   sensitivity analysis   studies

lopinavir/ritonavir in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias clinical improvementdetailed resultsHuang, 2020 (REV) 0.73 [0.39; 1.37] 0.73[0.39; 1.37]Huang, 2020 (REV)10%22NAnot evaluable clinical improvement (14-day)detailed resultsHuang, 2020 (REV) 0.73 [0.39; 1.37] 0.73[0.39; 1.37]Huang, 2020 (REV)10%22NAnot evaluable hospital dischargedetailed resultsHuang, 2020 (REV) 0.50 [0.29; 0.87] 0.50[0.29; 0.87]Huang, 2020 (REV)10%22NAnot evaluable radiologic improvement (14-day)detailed resultsHuang, 2020 (REV) 0.75 [0.53; 1.06] 0.75[0.53; 1.06]Huang, 2020 (REV)10%22NAnot evaluable radiologic improvement (7-day)detailed resultsHuang, 2020 (REV) 0.42 [0.04; 3.91] 0.42[0.04; 3.91]Huang, 2020 (REV)10%22NAnot evaluable viral clearance detailed resultsHuang, 2020 (REV) 0.83 [0.54; 1.29] 0.83[0.54; 1.29]Huang, 2020 (REV)10%22NAnot evaluable viral clearance by day 14detailed resultsHuang, 2020 (REV) 0.92 [0.80; 1.06] 0.92[0.80; 1.06]Huang, 2020 (REV)10%22NAnot evaluable viral clearance by day 7detailed resultsHuang, 2020 (REV) 0.83 [0.42; 1.67] 0.83[0.42; 1.67]Huang, 2020 (REV)10%22NAnot evaluable adverse eventsdetailed resultsHuang, 2020 (REV) 0.56 [0.04; 7.21] 0.56[0.04; 7.21]Huang, 2020 (REV)10%22NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-06-17 19:54 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 509 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons